Navigation Links
Halozyme Reports First Quarter 2012 Financial Results
Date:5/7/2012

ater convenience to patients versus the traditional IV method due to its less invasive administration route and quicker administration time (5 minutes versus 30 – 90 minutes).  
  • Roche reiterated their intent to file the Line Extension Application of subcutaneous MabThera® (rituxumab with rHuPH20) to the EMA this year for the treatment of Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia and Follicular Lymphoma.
  • Announced positive data with ViroPharma regarding a Phase 2 SC trial of Cinryze® (C1 esterase inhibitor [human]) in combination with rHuPH20, in patients with hereditary angioedema. Presented at the American Academy of Allergy Asthma & Immunology, the study demonstrated that SC co-administration of Cinryze with rHuPH20 was well tolerated and resulted in sustained physiologically relevant C1 INH functional concentrations.
  • Updated the Hylenex® recombinant (hyaluronidase human injection) label to include instructions for pre-administration of the enzyme in advance of other injected or subcutaneously infused drugs, and information from non-clinical studies that provide further data on the safety profile of Hylenex.
  • First Quarter 2012 Financial ResultsThe net loss for the first quarter of 2012 was $15.1 million, or $0.14 per share, compared with a net loss for the first quarter of 2011 of $9.6 million, or $0.10 per share.

  • Revenues for the first quarter of 2012 were $7.4 million, compared to $7.5 million for the first quarter of 2011. Revenues in the first quarter of 2012 primarily consisted of a milestone payment from Roche of $4 million and research and development reimbursements from partners.
  • Research and development expenses for the first quarter of 2012 were $15.9 million, compared with $13.8 million for the first quarter of 2011, primarily due to an increase in manufacturing activities and compensation costs, partially offset by a decrease in clinical trial act
    '/>"/>

  • SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Halozyme to Host First Quarter 2012 Financial Results Conference Call
    2. ViroPharma and Halozyme Announce Positive Data of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Recombinant Human Hyaluronidase (rHuPH20)
    3. Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
    4. Halozyme Announces Exercise in Full of Over-Allotment Option and Completion of Public Offering of Stock
    5. Halozyme Announces Proposed Public Offering of Common Stock
    6. ViroPharma and Halozyme Therapeutics Announce Positive Data From Initial Phase 2 Assessment of Subcutaneous Cinryze® (C1 esterase inhibitor [human]) with Hyaluronidase (rHuPH20)
    7. Halozyme Therapeutics Announces Positive Results From Enzyme-Augmented Insulin Pump Trial
    8. Halozyme Therapeutics to Present Data on PEGPH20 at the Upcoming 2011 EORTC-NCI-ASCO Annual Meeting
    9. Halozyme Announces Positive Results from Roches Subcutaneous Herceptin Phase 3 Trial
    10. Halozyme Begins Randomized, Controlled Clinical Trial with PEGPH20 in Patients with Advanced Pancreatic Cancer
    11. ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2 Evaluation of Subcutaneous Delivery of Cinryze® (C1 Esterase Inhibitor [Human]) with Hyaluronidase (rHuPH20)
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/19/2014)... , Dec. 18, 2014 Research and ... the addition of the "Micro Market Monitor: ... to their offering. ... treatment is progressing steadily, which has resulted in ... devices market. The main purpose of these dermatology ...
    (Date:12/19/2014)... 2014  Decision Resources Group finds that the laparoscopic ... will increase to a value of over $4.3 ... expansion in the large direct energy device market. In ... adopted due to the advantages they offer and as ... from Decision Resources Group,s coverage of the U.S. laparoscopic ...
    (Date:12/19/2014)... 2014  RESMED INC. (NYSE: RMD ) today ... year 2015 results on Thursday, January 22, 2015, after the ... ResMed,s results will be issued after 1:00 p.m. US Pacific ... operating results and future outlook. The earnings call ... and the live webcast of the call can be accessed ...
    Breaking Medicine Technology:Micro Market Monitor: North American Dermatology Diagnostic Devices Market 2Micro Market Monitor: North American Dermatology Diagnostic Devices Market 3U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3ResMed To Announce Second Quarter 2015 Results 2
    ... MOUNT PROSPECT, Ill., March 22, 2011 The National Association ... the prescription monitoring programs (PMPs) of North Dakota , ... agreements to participate in the PMP Interconnect ™ system, ... United States to be linked, providing a more effective means ...
    ... 22, 2011 The U.S. Food and Drug Administration ... Ann Arbor, Mich., and two of its officers, Mark ... Lincoln, vice president of Quality Assurance and Operations, have ... (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) The ...
    Cached Medicine Technology:Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 2Three States Sign on to Participate in NABP's Interconnected Prescription Monitoring System 3FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 2FDA: Michigan Heart-Lung Bypass Machine Manufacturer Enters Into Consent Decree 3
    (Date:12/20/2014)... December 20, 2014 Angeldress.co.uk, the distinguished ... great for worldwide dress fans. The company has recently ... and information. For the holiday season, Angeldress Blog ... special wedding apparel. , Angeldress.co.uk prides itself in offering ... level of service. All the company’s outfits are very ...
    (Date:12/20/2014)... San Francisco, CA (PRWEB) December 20, 2014 ... a Social Innovation company just launched first birthday focused ... the services, “MERRY BIRTHDAY MESSAGE” launched in both US ... , MERRY BIRTHDAY MESSAGE : http://merrybirthday.net/message/ , ... launching for everyone’s birthday around the world. , Features, ...
    (Date:12/20/2014)... Recently, AngelWeddingDress.com has introduced its special ... the coming Christmas. In the promotion, all buyers worldwide ... “We have something special for the women who are ... Moreover, our new collections of 2015 dresses have been ... at greatly discounted prices. Visit our website now before ...
    (Date:12/20/2014)... Xarelto bleeding lawsuits filed by men and ... other serious side effects will be consolidated in the ... pretrial proceedings, Wright & Schulte LLC reports. The U.S. ... Friday to transfer 21 Xarelto lawsuits and over 30 ... the Louisiana district court for coordination by Judge Eldon ...
    (Date:12/20/2014)... Parker & Sons, Inc. a focused and dedicated ... contractor services announces reaching a milestone by providing 40 ... Arizona. Parker and Sons is comprised of a reliable ... customer service the number one priority. The company was ... one service vehicle and has since grown to become ...
    Breaking Medicine News(10 mins):Health News:Trendy Professional Wedding Apparel Recommended by Angeldress Blog 2Health News:Atore, Inc. Releasing the First Birthday Portal 2Health News:AngelWeddingDress Has Introduced Its Special Offer For The Coming Christmas 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 2Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 3Health News:Xarelto Bleeding Lawsuits Consolidated To Louisiana Federal Court For Multi-District Litigation Reports Wright & Schulte LLC 4Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 2Health News:Parker & Sons Announces Reaching A Milestone By Providing 40 Years Of Dedicated Contractor Services For Homeowners Of Arizona 3
    ... people become less efficient at separating important from less ... Knowing this, clinicians may be able to train people ... information better, according to a report in the May ... Psychological Association. , Remembering what,s most important is ...
    ... PARK, Calif., May 4 Acclarent, Inc., the pioneer ... the treatment of chronic sinusitis, announced today that the ... 7,500,971, entitled "Devices, Systems and Methods for Treating Disorders ... This patent and Acclarent,s earlier 7,462,175 patent are ...
    ... Commonsense Steps to Prevent Spreading FluNORRISTOWN, Pa., May 3 ... Pennsylvania,s first laboratory-confirmed case of 2009 A/H1N1 in a ... a confirmed case, it is even more important for ... that can help prevent the spread of the flu," ...
    ... 2009) Identifying one of the processes that plays a ... one day lead to better vaccines and possibly more effective ... Texas Children,s Hospital in a report that appears in the ... work, Dr. Daniel Lacorazza, assistant professor of pathology at BCM, ...
    ... Journalistic Achievement Award Winners , ... New York, NY ... ABC News 20/20 are among winners receiving top honors in the ... Plastic Surgery (ASAPS). Selected from over 125 entries, this year,s ...
    ... of liposuction will be discussed by leading experts at the Annual Meeting ... the Mandalay Bay Hotel & Convention Center May 2-7, 2009. , ... ... will be discussed by leading experts at the Annual Meeting of the ...
    Cached Medicine News:Health News:Memory grows less efficient very early in Alzheimer's disease 2Health News:Acclarent, Inc. Granted Key Patent Covering Balloon Sinuplasty(TM) Technologies 2Health News:Governor Rendell Announces Pennsylvania's First Confirmed Case of 2009 A/H1N1 Flu 2Health News:Governor Rendell Announces Pennsylvania's First Confirmed Case of 2009 A/H1N1 Flu 3Health News:Process controlling T cell growth and production identified 2Health News:Aesthetic Society Awards Journalists' Commitment To Patient Education 2Health News:Aesthetic Society Awards Journalists' Commitment To Patient Education 3Health News:Liposuction Turns 20 2Health News:Liposuction Turns 20 3Health News:Liposuction Turns 20 4
    Agglutinating sera for serological identification of E. coli by slide and/or tube agglutination tests. Agglutinating sera are packaged 2 mL / vial....
    ... innovative E.coli 0157 latex ... definitive identification of E.coli ... of a proprietary antibody ... of cross-reactions with Escherichia ...
    Inquire...
    The Onar®Lp test system is an in vitro test for the qualitative diagnosis of legionella in clinical samples....
    Medicine Products: